中国药房2025，Vol.36Issue(12)：1488-1494,7.DOI:10.6039/j.issn.1001-0408.2025.12.12
基于真实世界数据的安罗替尼三线治疗晚期非小细胞肺癌的临床评价
Clinical evaluation of anlotinib in third-line treatment for advanced non-small cell lung cancer based on real-world data
摘要
Abstract
OBJECTIVE To evaluate the clinical value of anlotinib in third-line treatment for patients with advanced non-small cell lung cancer(NSCLC)through real-world data.METHODS Clinical data of patients with advanced NSCLC who received treatment at the First Affiliated Hospital of Anhui University of Chinese Medicine from February 2021 to December 2024 were retrospectively collected.They were divided into anlotinib group(27 cases,receiving anlotinib therapy)and immunotherapy group(22 cases,receiving immunotherapy agents alone or in combination with chemotherapy drugs)according to treatment regimens.The progression-free survival(PFS)and overall survival(OS)of patients were compared between the two groups,and the occurrence of adverse drug reactions during the treatment period was recorded.Using a partitioned survival model,an economic evaluation of the two treatment regimens was conducted with a cost-utility analysis approach from the perspective of the healthcare system.RESULTS The median PFS and OS of patients in the anlotinib group were 5.93 months and 11.27 months,respectively;the median PFS and OS of patients in the immunotherapy group were 5.33 months and 9.77 months,respectively;the difference was not statistically significant(P＞0.05).There was no statistical difference in the total incidence of adverse drug reactions and grade 3-4 serious adverse drug reactions between the two groups(P＞0.05).Compared with the immunotherapy group,the incremental cost-effectiveness ratio of the anlotinib group was 1 806 724.60 yuan/quality-adjusted life year(QALY),which was significantly higher than three times China's per capita gross domestic product in 2024(287 247 yuan/QALY).CONCLUSIONS For third-line treatment of advanced NSCLC patients,the efficacy of anlotinib is no worse than that of immunotherapy alone or in combination with chemotherapy drugs,and the safety of the two groups is comparable.However,anlotinib is not cost-effective.关键词
安罗替尼/晚期非小细胞肺癌/三线治疗/免疫治疗/真实世界数据/有效性/安全性/经济性Key words
anlotinib/advanced non-small cell lung cancer/third-line treatment/immunotherapy/real-world data/efficacy/safety/economics分类
医药卫生引用本文复制引用
吴健,李培培,祝永福,张东伟,汪永忠,陈浩..基于真实世界数据的安罗替尼三线治疗晚期非小细胞肺癌的临床评价[J].中国药房,2025,36(12):1488-1494,7.基金项目
国家中医优势专科(临床药学)建设单位项目(No.国中医药医政函[2024]90号) （临床药学）
安徽省卫生健康委员会盐酸安罗替尼胶囊临床综合评价工作项目(No.K2023047) （No.K2023047）
